Review Article| Volume 167, ISSUE 1, P183-191, January 2016

Download started.


Therapeutic targeting of acute lung injury and acute respiratory distress syndrome

      There is no Food and Drug Administration-approved treatment for acute respiratory distress syndrome (ARDS), in spite of the relatively large number of patients with the diagnosis. In this report, we provide an overview of preclinical studies and a description of completed and future clinical trials in humans with ARDS. Preclinical studies dealing with acute lung injury have suggested roles for complement and complement receptors, as well as the evolving role of histones, but details of these pathways are inadequately understood. Anti-inflammatory interventions have not been convincingly effective. Various cell growth factors are being considered for clinical study. Interventions to block complement activation or its products are under consideration. Stem cell therapies have shown efficacy in preclinical studies, which have motivated phase I/II trials in humans with ARDS.


      AEC (alveolar epithelial cell), ALI (acute lung injury), ARDS (acute respiratory distress syndrome), BALF (bronchoalveolar lavage fluid), DAMPs (danger-associated molecular patterns), GM-CSF (granulocyte-macrophage colony-stimulating factor), IR (ischemia-reperfusion), LPS (lipopolysaccharide), NETs (neutrophil extracellular traps), PAMPs (pathogen-associated molecular patterns), PMNs (polymorphonuclear leukocytes (neutrophils)), TLRs (toll-like receptors)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ware L.B.
        • Matthay M.A.
        The acute respiratory distress syndrome.
        N Engl J Med. 2000; 342: 1334-1349
        • Rubenfeld G.D.
        • Caldwell E.
        • Peabody E.
        • et al.
        Incidence and outcomes of acute lung injury.
        N Engl J Med. 2005; 353: 1685-1693
        • Hudson L.D.
        • Steinberg K.P.
        Epidemiology of acute lung injury and ARDS.
        Chest. 1999; 116: 74S-82S
        • Dever L.L.
        • Johanson Jr., W.G.
        Pneumonia complicating adult respiratory distress syndrome.
        Clin Chest Med. 1995; 16: 147-153
        • Marshall R.P.
        • Bellingan G.
        • Webb S.
        • et al.
        Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome.
        Am J Respir Crit Care Med. 2000; 162: 1783-1788
        • Bachofen M.
        • Weibel E.R.
        Structural alterations of lung parenchyma in the adult respiratory distress syndrome.
        Clin Chest Med. 1982; 3: 35-56
        • Anderson W.R.
        • Thielen K.
        Correlative study of adult respiratory distress syndrome by light, scanning, and transmission electron microscopy.
        Ultrastruct Pathol. 1992; 16: 615-628
        • Steinberg K.P.
        • Milberg J.A.
        • Martin T.R.
        • Maunder R.J.
        • Cockrill B.A.
        • Hudson L.D.
        Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome.
        Am J Respir Crit Care Med. 1994; 150: 113-122
        • Abraham E.
        Neutrophils and acute lung injury.
        Crit Care Med. 2003; 31: S195-S199
        • Lee W.L.
        • Downey G.P.
        Neutrophil activation and acute lung injury.
        Curr Opin Crit Care. 2001; 7: 1-7
        • Herold S.
        • Steinmueller M.
        • von Wulffen W.
        • et al.
        Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand.
        J Exp Med. 2008; 205: 3065-3077
        • Chesnutt A.N.
        • Matthay M.A.
        • Tibayan F.A.
        • Clark J.G.
        Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance.
        Am J Respir Crit Care Med. 1997; 156: 840-845
        • Horowitz J.C.
        • Cui Z.
        • Moore T.A.
        • et al.
        Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome.
        Am J Physiol Lung Cell Mol Physiol. 2006; 290: L415-L425
        • Abraham E.
        Coagulation abnormalities in acute lung injury and sepsis.
        Am J Respir Cell Mol Biol. 2000; 22: 401-404
        • Idell S.
        • James K.K.
        • Levin E.G.
        • et al.
        Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.
        J Clin Invest. 1989; 84: 695-705
        • Prabhakaran P.
        • Ware L.B.
        • White K.E.
        • Cross M.T.
        • Matthay M.A.
        • Olman M.A.
        Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury.
        Am J Physiol Lung Cell Mol Physiol. 2003; 285: L20-L28
        • Martin C.
        • Papazian L.
        • Payan M.J.
        • Saux P.
        • Gouin F.
        Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients.
        Chest. 1995; 107: 196-200
        • Matute-Bello G.
        • Downey G.
        • Moore B.B.
        • et al.
        An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.
        Am J Respir Cell Mol Biol. 2011; 44: 725-738
        • Matute-Bello G.
        • Frevert C.W.
        • Martin T.R.
        Animal models of acute lung injury.
        Am J Physiol Lung Cell Mol Physiol. 2008; 295: L379-L399
        • Grommes J.
        • Soehnlein O.
        Contribution of neutrophils to acute lung injury.
        Mol Med. 2011; 17: 293-307
        • Beilman G.
        Pathogenesis of oleic acid-induced lung injury in the rat: distribution of oleic acid during injury and early endothelial cell changes.
        Lipids. 1995; 30: 817-823
        • Osterholzer J.J.
        • Christensen P.J.
        • Lama V.
        • et al.
        PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury.
        J Pathol. 2012; 228: 170-180
        • Osterholzer J.J.
        • Olszewski M.A.
        • Murdock B.J.
        • et al.
        Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury.
        J Immunol. 2013; 190: 3447-3457
        • Harkin D.W.
        • Marron C.D.
        • Rother R.P.
        • Romaschin A.
        • Rubin B.B.
        • Lindsay T.F.
        C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm.
        Br J Surg. 2005; 92: 1227-1234
        • Harkin D.W.
        • Romaschin A.
        • Taylor S.M.
        • Rubin B.B.
        • Lindsay T.F.
        Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm.
        J Vasc Surg. 2004; 39: 196-206
        • Groeneveld A.B.
        • Raijmakers P.G.
        • Rauwerda J.A.
        • Hack C.E.
        The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function.
        Eur J Vasc Endovasc Surg. 1997; 14: 351-359
        • Bosmann M.
        • Grailer J.J.
        • Zhu K.
        • et al.
        Anti-inflammatory effects of beta2 adrenergic receptor agonists in experimental acute lung injury.
        FASEB J. 2012; 26: 2137-2144
        • Guo R.F.
        • Ward P.A.
        Role of oxidants in lung injury during sepsis.
        Antioxid Redox Signal. 2007; 9: 1991-2002
        • Newton K.
        • Dixit V.M.
        Signaling in innate immunity and inflammation.
        Cold Spring Harb Perspect Biol. 2012; 4
        • Zhang Q.
        • Raoof M.
        • Chen Y.
        • et al.
        Circulating mitochondrial DAMPs cause inflammatory responses to injury.
        Nature. 2010; 464: 104-107
        • Bosmann M.
        • Ward P.A.
        Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.
        Adv Exp Med Biol. 2012; 946: 147-159
        • Bosmann M.
        • Grailer J.J.
        • Ruemmler R.
        • et al.
        Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury.
        FASEB J. 2013; 27: 5010-5021
        • Fattahi F.
        • Grailer J.J.
        • Jajou L.
        • Zetoune F.S.
        • Andjelkovic A.V.
        • Ward P.A.
        Organ distribution of histones after intravenous infusion of FITC histones or after sepsis.
        Immunol Res. 2015; 61: 177-186
        • Tschopp J.
        • Schroder K.
        NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?.
        Nat Rev Immunol. 2010; 10: 210-215
        • Allam R.
        • Darisipudi M.N.
        • Tschopp J.
        • Anders H.J.
        Histones trigger sterile inflammation by activating the NLRP3 inflammasome.
        Eur J Immunol. 2013; 43: 3336-3342
        • Grailer J.J.
        • Canning B.A.
        • Kalbitz M.
        • et al.
        Critical role for the NLRP3 inflammasome during acute lung injury.
        J Immunol. 2014; 192: 5974-5983
        • Xu J.
        • Zhang X.
        • Pelayo R.
        • et al.
        Extracellular histones are major mediators of death in sepsis.
        Nat Med. 2009; 15: 1318-1321
        • Liu L.
        • He H.
        • Liu A.
        • et al.
        Therapeutic effects of bone marrow-derived mesenchymal stem cells in models of pulmonary and extrapulmonary acute lung injury.
        Cell Transplant. 2015; ([Epub ahead of print])
        • Vaughan A.E.
        • Brumwell A.N.
        • Xi Y.
        • et al.
        Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury.
        Nature. 2015; 517: 621-625
        • Laudes I.J.
        • Chu J.C.
        • Sikranth S.
        • et al.
        Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.
        Am J Pathol. 2002; 160: 1867-1875
        • Jones H.D.
        • Crother T.R.
        • Gonzalez-Villalobos R.A.
        • et al.
        The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury.
        Am J Respir Cell Mol Biol. 2014; 50: 270-280
        • Uriarte S.M.
        • Rane M.J.
        • Merchant M.L.
        • et al.
        Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats.
        Shock. 2013; 39: 286-292
        • Wildhagen K.C.
        • Garcia de Frutos P.
        • Reutelingsperger C.P.
        • et al.
        Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis.
        Blood. 2014; 123: 1098-1101
      1. The identity problem.
        Nat Biotechnol. 2010; 28: 877
        • Kalliolias G.D.
        • Liossis S.N.
        The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
        Expert Opin Investig Drugs. 2008; 17: 349-359
        • Liu D.
        • Lon H.K.
        • Dubois D.C.
        • Almon R.R.
        • Jusko W.J.
        Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.
        J Pharmacokinet Pharmacodyn. 2011; 38: 769-786
        • The Acute Respiratory Distress Syndrome Network
        Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network.
        N Engl J Med. 2000; 342: 1301-1308
        • Luce J.M.
        • Montgomery A.B.
        • Marks J.D.
        • Turner J.
        • Metz C.A.
        • Murray J.F.
        Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock.
        Am Rev Respir Dis. 1988; 138: 62-68
        • Steinberg K.P.
        • Hudson L.D.
        • Goodman R.B.
        • et al.
        Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
        N Engl J Med. 2006; 354: 1671-1684
        • Meduri G.U.
        • Golden E.
        • Freire A.X.
        • et al.
        Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.
        Chest. 2007; 131: 954-963
        • Iwata K.
        • Doi A.
        • Ohji G.
        • et al.
        Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis.
        Intern Med. 2010; 49: 2423-2432
        • Takano Y.
        • Mitsuhashi H.
        • Ueno K.
        1alpha,25-Dihydroxyvitamin D(3) inhibits neutrophil recruitment in hamster model of acute lung injury.
        Steroids. 2011; 76: 1305-1309
        • Parekh D.
        • Dancer R.C.
        • Lax S.
        • et al.
        Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial.
        Trials. 2013; 14: 100
        • Fisher B.J.
        • Kraskauskas D.
        • Martin E.J.
        • et al.
        Attenuation of sepsis-induced organ injury in mice by vitamin C.
        JPEN J Parenter Enteral Nutr. 2014; 38: 825-839
        • Ware L.B.
        • Matthay M.A.
        Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair.
        Am J Physiol Lung Cell Mol Physiol. 2002; 282: L924-L940
        • Wu H.
        • Suzuki T.
        • Carey B.
        • Trapnell B.C.
        • McCormack F.X.
        Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages.
        J Biol Chem. 2011; 286: 14932-14940
        • Paine 3rd, R.
        • Standiford T.J.
        • Dechert R.E.
        • et al.
        A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury.
        Crit Care Med. 2012; 40: 90-97
        • Presneill J.J.
        • Harris T.
        • Stewart A.G.
        • Cade J.F.
        • Wilson J.W.
        A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.
        Am J Respir Crit Care Med. 2002; 166: 138-143
        • Rosenbloom A.J.
        • Linden P.K.
        • Dorrance A.
        • Penkosky N.
        • Cohen-Melamed M.H.
        • Pinsky M.R.
        Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients.
        Chest. 2005; 127: 2139-2150
        • Orozco H.
        • Arch J.
        • Medina-Franco H.
        • et al.
        Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
        Arch Surg. 2006; 141 (discussion 4): 150-153
        • Meisel C.
        • Schefold J.C.
        • Pschowski R.
        • et al.
        Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
        Am J Respir Crit Care Med. 2009; 180: 640-648
        • Mason R.J.
        • Leslie C.C.
        • McCormick-Shannon K.
        • et al.
        Hepatocyte growth factor is a growth factor for rat alveolar type II cells.
        Am J Respir Cell Mol Biol. 1994; 11: 561-567
        • Mason R.J.
        • McCormick-Shannon K.
        • Rubin J.S.
        • Nakamura T.
        • Leslie C.C.
        Hepatocyte growth factor is a mitogen for alveolar type II cells in rat lavage fluid.
        Am J Physiol. 1996; 271: L46-L53
        • Panos R.J.
        • Patel R.
        • Bak P.M.
        Intratracheal administration of hepatocyte growth factor/scatter factor stimulates rat alveolar type II cell proliferation in vivo.
        Am J Respir Cell Mol Biol. 1996; 15: 574-581
        • Singh-Kaw P.
        • Zarnegar R.
        • Siegfried J.M.
        Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells.
        Am J Physiol. 1995; 268: L1012-L1020
        • Idell S.
        Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
        Crit Care Med. 2003; 31: S213-S220
        • Dixon B.
        • Schultz M.J.
        • Smith R.
        • Fink J.B.
        • Santamaria J.D.
        • Campbell D.J.
        Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial.
        Crit Care. 2010; 14: R180
        • Erlich J.M.
        • Talmor D.S.
        • Cartin-Ceba R.
        • Gajic O.
        • Kor D.J.
        Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study.
        Chest. 2011; 139: 289-295
        • Igonin A.A.
        • Protsenko D.N.
        • Galstyan G.M.
        • et al.
        C1-esterase inhibitor infusion increases survival rates for patients with sepsis*.
        Crit Care Med. 2012; 40: 770-777
        • Islam M.N.
        • Das S.R.
        • Emin M.T.
        • et al.
        Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury.
        Nat Med. 2012; 18: 759-765
        • Matthay M.A.
        • Goolaerts A.
        • Howard J.P.
        • Lee J.W.
        Mesenchymal stem cells for acute lung injury: preclinical evidence.
        Crit Care Med. 2010; 38: S569-S573
        • Lee J.W.
        • Krasnodembskaya A.
        • McKenna D.H.
        • Song Y.
        • Abbott J.
        • Matthay M.A.
        Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria.
        Am J Respir Crit Care Med. 2013; 187: 751-760
        • Gupta N.
        • Su X.
        • Popov B.
        • Lee J.W.
        • Serikov V.
        • Matthay M.A.
        Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice.
        J Immunol. 2007; 179: 1855-1863
        • Zheng G.
        • Huang L.
        • Tong H.
        • et al.
        Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
        Respir Res. 2014; 15: 39
        • Wilson J.G.
        • Liu K.D.
        • Zhuo H.
        • et al.
        Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
        Lancet Respir Med. 2015; 3: 24-32
        • Liu K.D.
        • Wilson J.G.
        • Zhuo H.
        • et al.
        Design and implementation of the START (STem cells for ARDS treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.
        Ann Intensive Care. 2014; 4: 22
        • Eisner M.D.
        • Thompson T.
        • Hudson L.D.
        • et al.
        Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome.
        Am J Respir Crit Care Med. 2001; 164: 231-236